Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity

Lei Hu 1,2, Shu-Hui Chen 3, Qiao-Li Lv 1,2, Bao Sun 1,2, Qiang Qu 4, Chong-Zhen Qin 5, Lan Fan 1,2, Ying Guo 1,2, Lin Cheng 6 and Hong-Hao Zhou 1,2,*

1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; hu773589905@163.com (L.H.); lvqiaoli2008@126.com (Q.-L.L.); scy.csu2016@163.com (B.S.); fanlan_038038@163.com (L.F.); guoying881212@csu.edu.cn (Y.G.)
2 Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
3 Department of Oncology, Changsha Central Hospital, Changsha 410006, China; chenshuhui2008@126.com
4 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, China; quqiang1983@sina.com
5 Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Central South University, Zhengzhou 450052, China; qcz0378@126.com
6 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China; kjade.cheng@hotmail.com
* Correspondence: hhzhou2003@163.com; Tel.: +86-731-8480-5380; Fax: +86-731-8235-4476

Academic Editor: Paul B. Tchounwou

Received: 9 March 2016; Accepted: 20 May 2016; Published: 30 May 2016

Abstract: Long non-coding RNA (lncRNA) CASC8 rs10505477 polymorphism has been identified to be related to risk of many kinds of cancers, such as colorectal cancer, gastric cancer, and invasive ovarian cancer, and it may be involved in the prognosis of gastric cancer patients who have received platinum-based chemotherapy after surgical treatment. So far, there is no study investigating the clinical significance of lncRNA CASC8 rs10505477 in lung cancer susceptibility and treatment. In this study, we genotyped 498 lung cancer patients and 213 healthy control subjects to explore the correlation between the rs10505477 polymorphism and lung cancer risk in a Chinese population. Among the 498 patients, 467 were selected for the chemotherapy response and toxicity study. We found that the single nucleotide polymorphisms (SNP) rs10505477 was greatly related to lung cancer risk in male and adenocarcinoma subgroups in recessive model (adjusted OR = 0.51, 95%CI = 0.29–0.90, p = 0.02; adjusted OR = 0.52, 95%CI = 0.30–0.89, p = 0.02, respectively). It was also closely correlated with platinum-based chemotherapy response in dominant model (adjusted OR = 1.58, 95%CI = 1.05–2.39, p = 0.03). Additionally, we observed that CASC8 rs10505477 polymorphism was significantly relevant to severe hematologic toxicity in non-small-cell lung cancer (NSCLC) subgroup in dominant model (adjusted OR = 0.59, 95%CI = 0.35–0.98, p = 0.04) and in additive model (adjusted OR = 0.62, 95%CI = 0.43–0.90, p = 0.01). Furthermore, it was found that rs10505477 polymorphism was greatly associated with gastrointestinal toxicity in SCLC and cisplatin subgroups in dominant model (adjusted OR = 7.82, 95%CI = 1.36–45.07, p = 0.02; adjusted OR = 1.94, 95%CI = 1.07–3.53, p = 0.03, respectively). Thus, lncRNA CASC8 rs10505477 could serve as a possible risk marker for diagnosing lung cancer, and could be used to forecast the response and toxicity of platinum-based treatment in lung cancer patients.

Keywords: lncRNA CASC8; rs10505477; lung cancer; susceptibility; platinum-based chemotherapy
1. Introduction

Lung cancer, containing two primary subtypes: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), is a major cause of cancer-related death globally, with an extremely poor overall survival rate [1]. NSCLC, accounting for the most of lung cancers, approximately 85%, could be further classified as squamous-cell carcinoma (SCC), adenocarcinoma (ADC), and large-cell carcinoma [2]. Although cigarette smoking is a well-known major risk factor, genetic factors are also reported to be associated with lung cancer susceptibility [3–5]. Platinum-based cytotoxic chemotherapy, one of the various treatment options in clinic, is the standard first-line treatment for lung cancer. However, low objective response rate (ORR) or serious toxicity reaction in some lung cancer patients is often observed in clinic. In brief, late diagnosis, chemo-resistance, and toxicity are considered to be major factors that contributed to the poor outcome of lung cancer patients. Therefore, it is urgent to seek out new biomarkers that can accurately predetermine the susceptibility, chemotherapy response, and/or toxicity for lung cancer patients.

So far, a great number of genes have been found to be related to lung carcinogenesis [6,7], efficacy, or toxicity of platinum-based chemotherapy [8–11]. Although focusing on known genes might yield further understanding in progress and therapy of lung cancer, newly-developed markers such as long non-coding RNAs (lncRNAs) may lead novel insight into the mechanism of lung cancer risk or therapy.

lncRNAs are often considered to be a kind of non-coding RNA over 200 bases with no protein-coding function. lncRNAs aroused people’s widespread interest since their transcriptional function were first identified in mouse by Okazaki et al. [12]. There has been a growing body of research demonstrating that lncRNAs can participate in gene expression regulation at different levels including modification of chromatin [13], transcription, and post-transcriptional processing [14], involving in various aspects of biological processes, having many kinds of functions in different physiological and pathological processes, and playing vital roles in tumorigenesis and drug efficacy [2,15]. Currently, a number of dysregulated lncRNAs have been identified in various cancers, including lung carcinoma [16–19]. The aberrant expression of lncRNAs may have important significance in the diagnosis and therapy of cancers, especially lung cancer.

Single nucleotide polymorphisms (SNP) could significantly affect gene expression and function. Increasing evidence demonstrates that SNPs in some lncRNAs are related to tumorigenesis and chemotherapy response [2,20,21]. Gong et al., found that HOTTIP rs1859168 or rs883064, H19 rs2107425, and CCAT2 rs6983267 showed strong relationship with risk of lung cancer, MALAT1 rs619586, H19 rs2107425 or rs2839698, CCAT2 rs6983267, HOTAIR rs1899663, or rs7958904 and ANRIL rs10120688 or rs1333049 were associated with platinum-based chemotherapy response for lung cancer patients [2]. Cancer susceptibility candidate 8 (CASC8) gene, a long non-coding RNA, is located in the region of 8q24, which is a gene desert region with no ability of protein coding [22]. Recent evidence suggested that CASC8 gene polymorphism, such as rs7837328, rs7014346, rs6983267, play important roles in various cancers including prostate cancer [23], breast cancer, colorectal cancer (CRC), and gastric cancer [22]. The SNP rs10505477, located in the intron of lncRNA CASC8, showed strong association with the risk of CRC [24–26] and the prognosis of gastric cancer [22]. However, to our best knowledge, the implication of lncRNA CASC8 rs10505477 in lung cancer remains unclear. In present study, we evaluated the relationship of CASC8 rs10505477 to lung cancer susceptibility, platinum-based chemotherapy response, and toxicity.

2. Subjects and Methods

2.1. Subjects

The ethics committee of Xiangya School of Medicine of Central South University (Changsha, China) approved this case-control study (registration CTXY-1100082 and CTXY-1100083). Four-hundred and ninety-eight lung cancer patients with histologically or cytologically confirmed primary lung cancer were recruited from Xiangya Hospital and the Affiliated Cancer Hospital of
Central South University from November 2011 and May 2013. Two-hundred thirteen healthy controls were from health examination center of Xiangya Hospital of Central South University. All of the subjects were unrelated ethnic Chinese and provided written informed consent.

The patients that had leptomeningeal metastases or symptomatic brain, active infection, lactation, pregnancy, and other malignant tumors were ruled out from this study. Thus, 467 lung cancer patients were selected for the chemotherapy response and toxicity investigation, satisfying the following conditions: (1) biological therapy and/or radiotherapy were not given before and during chemical therapy; (2) received at least two cycles of chemotherapy treatment; (3) encountered complete follow-up after drug administration; and (4) same methods of imaging were conducted to assess the tumors before and during platinum-based treatment. The platinum-based chemotherapy regimens involved for these selected patients including: platinum with gemcitabine (GP), etoposide (EP), pemetrexed (PP), docetaxel (DP), and paclitaxel (TP), and other platinum-based regimens (platinum with irinotecan or navelbine).

2.2. Data Collection

Demographic data and information including sex, age, race, and tumor, node, metastasis (TNM) stages were collected. ORR were estimated on the basis of guidelines as described in Response Evaluation Criteria in Solid Tumors (RECIST) [27]. For data analysis in our study, responders were defined as partial response (PR) and complete response (CR), while non-responders as progressive disease (PD), and stable disease (SD). Toxicities, those related to platinum-based chemotherapy, including gastrointestinal toxicity (diarrhea, nausea and vomiting) and hematologic toxicity (thrombocytopenia, anemia, leucopenia and neutropenia) were evaluated according to the National Cancer Institute Common Toxicity Criteria Version 3.0 (http://ctep.cancer.gov). Severe overall toxicity required the presence of grade 3 or 4 gastrointestinal or hematologic toxicity.

2.3. DNA Extraction and Genotyping

Genomic DNA was extracted from the peripheral blood of the subjects using Genomic DNA Purification Kit (Promega, Madison, WI, USA) or FlexiGene DNA Kit (Qiagen, Hilden, Germany) according to the manufacturer’s directions. The DNA was stored at −20 °C until use. The SNP genotyping analysis was performed using the Sequenom MassARRAY system (Sequenom, San Diego, CA, USA). For quality control, DNA sequencing on a random 5% of all samples was conducted to confirm the genotypes, the reproducibility was 100%.

2.4. Statistical Analysis

A χ-square test was conducted to evaluate the differences in the distributions of demographic characteristics between lung cancer cases and controls. The goodness-of-fit χ-square test was performed to estimate the Hardy-Weinberg equilibrium for controls. Bivariate logistical regression analysis was used to determine odd ratio (OR), 95% confidence interval (95%CI), and the corresponding p value for lung cancer risk analysis, with age and gender as covariates. Bivariate logistical regression analysis was also performed to calculate OR, 95%CI and p value of the association of CASC8 rs10505477 polymorphism with chemotherapy response and toxicity outcomes with sex, age, smoking status, stage, histological type, and chemotherapy regimens adjusted. p values that less than 0.05 were used for statistical significance. All data were analyzed using PASW Statistics v18.0 (IBM Co., Armonk, NY, USA) and PLINK 1.9 [28].

3. Results

3.1. Characteristics of Subjects

Four-hundred ninety-eight lung cancer patients (189 with squamous cell carcinoma, 217 with adenocarcinoma, 69 with small cell carcinoma, and 23 with others) and 213 healthy control subjects...
were recruited in our study. Table 1 provides a summary of the demographic characteristics distributions of subjects included in our study. Among the 498 cases, 467 were selected for chemotherapy response and toxicity analysis, and the clinical features were summarized in Table 2. The call rate of the SNP rs10505477 is 97.61%. The frequency of CASC8 rs10505477 G allele (43.49%, 45.95% in cases and controls, respectively) is highly similar to that recorded by NCBI, which reported a minor allele frequency (MAF) of 42.31%. Among controls, the observed genotype distributions of CASC8 rs10505477 were in Hardy-Weinberg equilibrium (HWE) ($p = 0.68$).

### Table 1. Subjects characteristics.

| Characteristics          | Patients, n (%) | Controls, n (%) | $p$  |
|--------------------------|-----------------|-----------------|------|
|                          | ($n = 498$)     | ($n = 213$)     |      |
| Sex                      |                 |                 |      |
| Male                     | 394 (79.12)     | 80 (37.56)      | 0.00 *|
| Female                   | 104 (20.88)     | 133 (62.44)     |      |
| Age (years)              |                 |                 |      |
| <50                      | 124 (24.90)     | 95 (44.60)      | 0.00 *|
| ≥50                      | 374 (75.10)     | 118 (55.40)     |      |
| Histology                |                 |                 |      |
| Non-small-cell lung cancer | 406 (81.53)  | 189 (37.95)     |      |
| Squamous-cell carcinoma  | 217 (43.57)     | 19 (42.40)      |      |
| Adenocarcinoma           | 69 (13.86)      | 35 (16.38)      |      |
| Small-cell lung cancer   | 23 (4.62)       | 17 (7.94)       |      |
| Other                    |                 |                 |      |
| Stage (Non-small-cell lung cancer) | 13 (3.03) | 115 (26.81) | 0.00 * |
| I, II                    | 13 (3.03)       | 115 (26.81)     |      |
| III                      | 115 (26.81)     | 11 (26.81)      |      |
| IV                       | 301 (70.16)     | 21 (47.83)      |      |
| Stage (Small-cell lung cancer) | 36 (52.17) | 33 (47.83) |      |
| Limited                  | 36 (52.17)      | 33 (47.83)      |      |
| Extensive                | 33 (47.83)      | 33 (47.83)      |      |

Other: Mixed-cell or undifferentiated carcinoma; *$p < 0.05$.

### Table 2. Association of chemotherapy responses with clinical pathologic features.

| Clinical Pathological Features | Response to Chemotherapy | $p$  |
|-------------------------------|--------------------------|------|
|                               | CR + PR, n (%) | PD + SD, n (%) |      |
| All                           | 184 (100.00)       | 283 (100.00)   |      |
| Gender                        |                 |                 |      |
| Female                        | 28 (15.22)        | 68 (24.03)      |      |
| Male                          | 156 (84.78)       | 215 (75.97)     | 0.03 *|
| Age(years)                    |                 |                 |      |
| <57                           | 89 (48.37)        | 145 (51.24)     | 0.57  |
| ≥57                           | 95 (51.63)        | 138 (48.76)     |      |
| History of smoking            |                 |                 |      |
| Yes                           | 123 (66.85)       | 163 (57.60)     | 0.05  |
| No                            | 61 (33.15)        | 120 (42.40)     |      |
| Histology                     |                 |                 |      |
| Non-small-cell lung cancer    | 130 (70.65)       | 241 (85.16)     |      |
| Squamous-cell carcinoma       | 76 (41.30)        | 91 (32.16)      |      |
| Adenocarcinoma                | 54 (29.35)        | 150 (53.00)     | 0.00 *|
| Small-cell lung cancer        | 42 (22.83)        | 26 (9.19)       |      |
| Other                         | 12 (6.52)         | 16 (5.65)       |      |
| Stage (Non-small-cell lung cancer) | 5 (3.42) | 8 (3.11) | 0.90  |
| I, II                         | 5 (3.42)          | 8 (3.11)        |      |
| III, IV                       | 141 (96.58)       | 249 (96.89)     |      |
| Stage (Small-cell lung cancer) |                 |                 |      |
Table 2. Cont.

| Clinical Pathological Features | Response to Chemotherapy | p  |
|--------------------------------|---------------------------|----|
|                                | CR + PR, n (%)             | PD + SD, n (%) |
| Limited                        | 26 (61.90)                 | 13 (50.00)    | 0.45 |
| Extensive                      | 16 (38.10)                 | 13 (50.00)    |     |
| Chemotherapy regimen           |                           |               |     |
| Platinum/gemcitabine           | 82 (44.57)                 | 110 (38.87)   |     |
| Platinum/etoposide             | 43 (23.37)                 | 25 (8.83)     |     |
| Platinum/pemetrexed            | 35 (19.02)                 | 102 (36.04)   | 0.00*|
| Platinum/paclitaxel            | 9 (4.89)                   | 18 (6.36)     |     |
| Platinum/docetaxel             | 9 (4.89)                   | 20 (7.07)     |     |
| Other a                        | 6 (3.26)                   | 8 (2.83)      |     |

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; Other a: Mixed-cell or undifferentiated carcinoma; Other b: Platinum/irinotecan or platinum/navelbine; * p < 0.05.

3.2. Relationship between CASC8 rs10505477 Polymorphism and Lung Cancer Risk

The relationship between IncRNA CASC8 rs10505477 polymorphism and lung cancer susceptibility was determined after sex and age adjusted. As shown in Table 3, CASC8 rs10505477 failed to be statistically related to lung cancer risk. However, the results of stratified analysis demonstrated that the SNP rs10505477 was significantly correlated with risk of lung cancer in male and ADC subgroups in recessive model (adjusted OR = 0.51, 95%CI = 0.29–0.90, p = 0.02; adjusted OR = 0.52, 95%CI = 0.30–0.89, p = 0.02, respectively, Table 4).

Table 3. Association between IncRNA CASC8 rs10505477 and lung cancer risk.

| Genotype | Case | Control | Dominant | Recessive | Additive |
|----------|------|---------|----------|-----------|----------|
|          | n (%)| n (%)   | OR (95%CI)| p          | OR (95%CI)| p        | OR (95%CI) | p        |
| GG       | 89 (18.39) | 46 (21.90) | 0.96 (0.65,1.42) | 0.83 | 0.68 (0.44,1.06) | 0.09 | 0.87 (0.67,1.12) | 0.27 |
| GA       | 243 (50.21) | 101 (48.10) |         |           |          |         |           |         |
| AA       | 152 (31.40) | 63 (30.00) |         |           |          |         |           |         |

OR: Odd ratio; CI: Confidence interval.

Table 4. Stratification analysis of the relationship between CASC8 rs10505477 and lung cancer risk.

| Subgroup               | Dominant | p     | Recessive | p     | Additive | p     |
|------------------------|----------|-------|-----------|-------|----------|-------|
|                        | OR (95%CI) |       | OR (95%CI) |       | OR (95%CI) |       |
| Age < 50               | 0.95 (0.52,1.76) | 0.88 | 0.78 (0.36,1.68) | 0.53 | 0.91 (0.60,1.38) | 0.65 |
| Age ≥ 50               | 0.96 (0.58,1.60) | 0.88 | 0.64 (0.37,1.11) | 0.11 | 0.84 (0.61,1.17) | 0.31 |
| Female                 | 1.03 (0.58,1.84) | 0.91 | 1.04 (0.53,2.06) | 0.91 | 1.03 (0.70,1.52) | 0.89 |
| Male                   | 0.90 (0.53,1.54) | 0.70 | 0.51 (0.29,0.90) | 0.02*| 0.76 (0.54,1.07) | 0.12 |
| Non-small-cell lung cancer | 1.04 (0.70,1.56) | 0.84 | 0.67 (0.42,1.06) | 0.09 | 0.89 (0.68,1.16) | 0.40 |
| Squamous-cell carcinoma | 0.82 (0.48,1.38) | 0.45 | 0.75 (0.42,1.33) | 0.32 | 0.84 (0.60,1.17) | 0.30 |
| Adenocarcinoma         | 1.16 (0.74,1.82) | 0.51 | 0.52 (0.30,0.89) | 0.02*| 0.87 (0.64,1.17) | 0.35 |
| Small-cell lung cancer | 0.71 (0.36,1.41) | 0.33 | 0.59 (0.28,1.26) | 0.17 | 0.74 (0.48,1.13) | 0.16 |
| Other                  | 0.72 (0.27,1.90) | 0.50 | 0.73 (0.24,2.22) | 0.58 | 0.79 (0.43,1.48) | 0.46 |

Other: Mixed-cell, or undifferentiated carcinoma; OR: Odd ratio; CI: Confidence interval; * p < 0.05.

3.3. Association between CASC8 rs10505477 Polymorphism and Chemotherapy Response in Lung Cancers

Of the 467 selected patients, 184 were recognized as responders, while 283 as non-responders. After sex, age, histological type, smoking status, stage, and chemotherapy regimens adjusted, it was observed that CASC8 rs10505477 was greatly correlated with platinum-based chemotherapy response in dominant model (adjusted OR = 1.58, 95%CI = 1.05–2.39, p = 0.03, Table 5). No association between
rs10505477 polymorphism and chemotherapy response was observed after stratification analysis (Table 6).

### Table 5. Association between CASC8 rs10505477 and chemotherapy response in lung cancers.

| Genotype | CR + PR | PD + SD | Dominant | Recessive | Additive |
|----------|---------|---------|----------|-----------|----------|
|          | n (%)   | n (%)   | OR (95%CI) | p   | OR (95%CI) | p   | OR (95%CI) | p   |
| GG       | 36 (19.25) | 49 (17.88) | 1.58 (1.05,2.39) | 0.03 * | 0.96 (0.57,1.59) | 0.86 | 1.22 (0.92,1.62) | 0.17 |
| GA       | 81 (43.32) | 149 (54.38) |         |       |           |     |           |     |
| AA       | 70 (37.43) | 76 (27.74) |         |       |           |     |           |     |

OR: Odd ratio; CI: Confidence interval; * p < 0.05.

### Table 6. Stratification analysis of association between CASC8 rs10505477 and response of platinum-based chemotherapy in lung cancers.

| Subgroup                  | Dominant | Recessive | Additive |
|---------------------------|----------|-----------|----------|
|                           | OR (95%CI) | p   | OR (95%CI) | p   | OR (95%CI) | p   |
| Age < 57                  | 1.54 (0.85,2.79) | 0.15 | 1.00 (0.47,2.15) | 0.99 | 1.24 (0.81,1.88) | 0.32 |
| Age ≥ 57                  | 1.56 (0.86,2.85) | 0.15 | 0.83 (0.40,1.69) | 0.60 | 1.15 (0.77,1.72) | 0.50 |
| Female                    | 1.87 (0.65,5.37) | 0.25 | 0.45 (0.13,1.59) | 0.21 | 1.04 (0.49,2.20) | 0.92 |
| Male                      | 1.44 (0.91,2.26) | 0.12 | 1.07 (0.61,1.89) | 0.83 | 1.20 (0.88,1.64) | 0.24 |
| Non-smoke                 | 1.75 (0.87,3.50) | 0.11 | 0.67 (0.27,1.64) | 0.38 | 1.18 (0.72,1.94) | 0.52 |
| Smoke                     | 1.62 (0.95,2.75) | 0.07 | 1.18 (0.63,2.22) | 0.60 | 1.30 (0.92,1.86) | 0.14 |
| Non-small-cell lung cancer| 1.60 (1.00,2.56) | 0.05 | 0.97 (0.53,1.77) | 0.93 | 1.24 (0.89,1.73) | 0.20 |
| Squamous-cell carcinoma   | 1.35 (0.69,2.61) | 0.38 | 1.07 (0.50,2.33) | 0.86 | 1.16 (0.75,1.78) | 0.50 |
| Adenocarcinoma            | 1.89 (0.95,3.77) | 0.07 | 1.11 (0.40,3.05) | 0.85 | 1.48 (0.86,2.52) | 0.15 |
| Small-cell lung cancer    | 1.91 (0.60,6.04) | 0.27 | 2.01 (0.49,8.21) | 0.33 | 1.63 (0.76,3.52) | 0.21 |
| Stage (III, IV)           | 1.48 (0.94,2.34) | 0.09 | 0.87 (0.50,1.52) | 0.63 | 1.15 (0.84,1.58) | 0.37 |
| Platinum/gemcitabine      | 1.45 (0.86,2.45) | 0.16 | 0.77 (0.28,2.16) | 0.62 | 1.60 (0.91,2.81) | 0.11 |
| Platinum/etoposide        | 1.46 (0.47,4.51) | 0.51 | 1.69 (0.44,6.51) | 0.45 | 1.37 (0.66,2.87) | 0.40 |
| Platinum/pemetrexed       | 1.68 (0.70,4.05) | 0.25 | 1.06 (0.29,3.80) | 0.93 | 1.36 (0.69,2.66) | 0.37 |

OR: Odd ratio; CI: Confidence interval.

### 3.4. Relationship between CASC8 rs10505477 Polymorphism and Hematologic, Gastrointestinal, or Overall Serious Toxicity Induced by Platinum-Based Chemotherapy in Lung Cancers

After sex, age, histological type, smoking status, stage, and chemotherapy regimens adjusted, we observed that CASC8 rs10505477 was not related to hematologic (Table 7), gastrointestinal (Table 8), or overall severe toxicity (Table 9) of platinum-based chemotherapy. Stratified analysis was performed to further assess the association of CASC8 rs10505477 with the toxicity induced by platinum-based chemotherapy. We found that CASC8 rs10505477 polymorphism was statistically correlated with severe hematologic toxicity in NSCLC subgroup in dominant and additive models (adjusted OR = 0.59, 95%CI = 0.35–0.98, p = 0.04 in dominant model; adjusted OR = 0.62, 95%CI = 0.43–0.90, p = 0.01 in additive model, Table 10). Additionally, it was observed that CASC8 rs10505477 polymorphism was related to gastrointestinal toxicity in SCLC and cisplatin subgroups in dominant model (adjusted OR = 7.82, 95%CI = 1.36–45.07, p = 0.02; adjusted OR = 1.94, 95%CI = 1.07–3.53, p = 0.03, respectively, Table 11). No relationship between CASC8 rs10505477 and overall severe toxicity was discovered when we performed a subtype analysis (Table 12).
Table 7. Association between CASC8 rs10505477 and platinum-based chemotherapy hematologic toxicity in lung cancers.

| Genotype | Tolerance | Severity | Dominant | Recessive | Additive |
|----------|-----------|----------|----------|-----------|----------|
|          | n (%)     | n (%)    | OR (95%CI) | p         | OR (95%CI) | p         | OR (95%CI) | p         |
| GG       | 61 (17.78) | 19 (17.27) | 1.13 (0.70,1.81) | 0.63      | 0.93 (0.52,1.65) | 0.79      | 1.03 (0.75,1.41) | 0.86      |
| GA       | 171 (49.85) | 58 (52.73) |          |           |          |          |          |           |
| AA       | 111 (32.36) | 33 (30.00) |          |           |          |          |          |           |

OR: Odd ratio; CI: Confidence interval.

Table 8. Association between CASC8 rs10505477 and platinum-based chemotherapy gastrointestinal toxicity in lung cancers.

| Genotype | Tolerance | Severity | Dominant | Recessive | Additive |
|----------|-----------|----------|----------|-----------|----------|
|          | n (%)     | n (%)    | OR (95%CI) | p         | OR (95%CI) | p         | OR (95%CI) | p         |
| GG       | 65 (18.47) | 15 (14.85) | 1.61 (0.96,2.71) | 0.07      | 0.80 (0.42,1.50) | 0.48      | 1.15 (0.83,1.61) | 0.40      |
| GA       | 168 (47.73) | 61 (60.40) |          |           |          |          |          |           |
| AA       | 119 (33.81) | 25 (24.75) |          |           |          |          |          |           |

OR: Odd ratio; CI: Confidence interval.

Table 9. Association between CASC8 rs10505477 and overall severe toxicity induced by platinum-based chemotherapy in lung cancers.

| Genotype | Tolerance | Severity | Dominant | Recessive | Additive |
|----------|-----------|----------|----------|-----------|----------|
|          | n (%)     | n (%)    | OR (95%CI) | p         | OR (95%CI) | p         | OR (95%CI) | p         |
| GG       | 53 (22.46) | 27 (15.25) | 1.22 (0.80,1.87) | 0.35      | 0.76 (0.45,1.29) | 0.31      | 1.01 (0.76,1.34) | 0.94      |
| GA       | 131 (55.51) | 98 (55.37) |          |           |          |          |          |           |
| AA       | 52 (22.03) | 52 (29.38) |          |           |          |          |          |           |

OR: Odd ratio; CI: Confidence interval.

Table 10. Stratification analysis of relationship between CASC8 rs10505477 and hematologic toxicity induced by platinum-based chemotherapy in lung cancers.

| Subgroup | Dominant | Recessive | Additive |
|----------|----------|-----------|----------|
|          | OR (95%CI) | p         | OR (95%CI) | p         | OR (95%CI) | p         |
| Age < 57 | 1.05 (0.53,2.08) | 0.90      | 0.97 (0.40,2.34) | 0.94      | 1.01 (0.63,1.63) | 0.96      |
| Age ≥ 57 | 1.14 (0.57,2.25) | 0.72      | 0.93 (0.42,2.04) | 0.85      | 1.03 (0.66,1.60) | 0.90      |
| Female   | 1.01 (0.50,3.33) | 0.99      | 0.50 (0.12,2.17) | 0.36      | 0.80 (0.36,1.78) | 0.59      |
| Male     | 1.13 (0.66,1.92) | 0.66      | 0.99 (0.52,1.90) | 0.98      | 1.05 (0.74,1.50) | 0.79      |
| Non-smoke| 1.52 (0.64,3.63) | 0.35      | 1.00 (0.34,2.83) | 0.96      | 1.20 (0.68,2.15) | 0.53      |
| Smoke    | 1.21 (0.66,2.20) | 0.54      | 1.10 (0.55,2.19) | 0.78      | 1.12 (0.76,1.65) | 0.58      |
| Non-small-cell lung cancer | 0.59 (0.35,0.98) | 0.04 * | 0.45 (0.21,0.99) | 0.05      | 0.62 (0.43,0.90) | 0.01 * |
| Squamous-cell carcinoma | 1.36 (0.63,2.91) | 0.44 | 1.42 (0.61,3.31) | 0.41 | 1.27 (0.78,2.05) | 0.34 |
| Adenocarcinoma | 1.05 (0.46,2.40) | 0.91 | 0.33 (0.07,1.52) | 0.16 | 0.80 (0.44,1.47) | 0.47 |
| Small-cell lung cancer | 0.92 (0.25,3.33) | 0.89 | 0.49 (0.08,2.84) | 0.43 | 0.80 (0.33,1.89) | 0.60 |
| Stage (III, IV) | 0.98 (0.58,1.65) | 0.93 | 0.82 (0.42,1.60) | 0.57 | 0.93 (0.65,1.33) | 0.70 |
| Cisplatin | 1.00 (0.59,1.70) | 1.00 | 0.92 (0.48,1.75) | 0.79 | 0.97 (0.68,1.39) | 0.88 |
| Carboplatin | 1.71 (0.55,5.28) | 0.35 | 0.93 (0.24,3.63) | 0.92 | 1.25 (0.59,2.63) | 0.56 |
| Platinum/gemcitabine | 1.04 (0.53,2.05) | 0.90 | 1.15 (0.53,2.52) | 0.72 | 1.07 (0.69,1.65) | 0.78 |
| Platinum/etoposide | 0.85 (0.26,2.76) | 0.79 | 0.33 (0.06,1.82) | 0.20 | 0.70 (0.32,1.56) | 0.38 |
| Platinum/pemetrexed | 1.02 (0.32,3.21) | 0.98 | 0.22 (0.02,2.29) | 0.20 | 0.74 (0.32,1.70) | 0.48 |

OR: Odd ratio; CI: Confidence interval; * p < 0.05.
Table 11. Stratification analysis of relationship between CASC8 rs10505477 and gastrointestinal toxicity induced by platinum-based chemotherapy in lung cancers.

| Subgroup                   | Dominant (OR 95%CI) p | Recessive (OR 95%CI) p | Additive (OR 95%CI) p |
|----------------------------|------------------------|------------------------|----------------------|
| Age < 57                   | 1.46 (0.75,2.85) 0.26  | 0.99 (0.44,2.25) 0.98  | 1.19 (0.76,1.86) 0.44|
| Age ≥ 57                   | 2.11 (0.87,5.15) 0.10  | 0.63 (0.23,1.77) 0.38  | 1.18 (0.70,1.97) 0.54|
| Female                     | 1.36 (0.48,3.83) 0.56  | 0.59 (0.17,2.09) 0.41  | 0.97 (0.49,1.92) 0.93|
| Male                       | 1.57 (0.86,2.86) 0.14  | 0.83 (0.40,1.72) 0.62  | 1.15 (0.79,1.69) 0.47|
| Non-smoke                  | 1.36 (0.60,3.08) 0.46  | 0.33 (0.09,1.21) 0.10  | 0.89 (0.51,1.55) 0.68|
| Smoke                      | 1.80 (0.90,3.59) 0.10  | 1.14 (0.54,2.38) 0.73  | 1.32 (0.87,2.02) 0.19|
| Non-small-cell lung cancer | 1.31 (0.72,2.38) 0.37  | 0.73 (0.34,1.56) 0.41  | 1.03 (0.70,1.53) 0.87|
| Squamous-cell carcinoma    | 1.18 (0.51,2.74) 0.70  | 0.91 (0.34,2.40) 0.85  | 1.04 (0.61,1.77) 0.89|
| Adenocarcinoma             | 1.56 (0.65,3.75) 0.32  | 0.48 (0.13,1.75) 0.26  | 1.03 (0.57,1.86) 0.92|
| Small-cell lung cancer     | 7.82 (1.36,45.07) 0.02* | 1.61 (0.28,9.07) 0.59  | 2.81 (0.99,7.93) 0.05|
| Stage (III, IV)            | 1.48 (0.85,2.55) 0.16  | 0.71 (0.36,1.42) 0.33  | 1.08 (0.76,1.53) 0.68|
| Cisplatin                  | 1.94 (1.07,3.53) 0.03* | 0.96 (0.50,1.86) 0.91  | 1.30 (0.90,1.88) 0.16|
| Carboplatin                | 1.06 (0.31,3.56) 0.93  | 0.39 (0.04,3.42) 0.39  | 0.69 (0.28,1.73) 0.43|
| Platinum/gemcitabine       | 0.90 (0.42,1.91) 0.78  | 0.93 (0.38,2.30) 0.88  | 0.53 (0.27,1.05) 0.09|
| Platinum/etoposide         | 0.53 (0.15,1.88) 0.32  | 2.03 (0.26,15.84) 0.50 | 0.78 (0.28,2.15) 0.63|
| Platinum/pemetrexed        | 2.06 (0.66,3.56) 0.21  | 2.35 (0.71,7.80) 0.16  | 0.83 (0.39,1.74) 0.62|

OR: Odd ratio; CI: Confidence interval; * p < 0.05.

Table 12. Stratification analysis of relationship between CASC8 rs10505477 and overall severe toxicity induced by platinum-based chemotherapy in lung cancers.

| Subgroup                   | Dominant (OR 95%CI) p | Recessive (OR 95%CI) p | Additive (OR 95%CI) p |
|----------------------------|------------------------|------------------------|----------------------|
| Age < 57                   | 1.16 (0.64,2.12) 0.63  | 0.92 (0.43,1.96) 0.83  | 1.05 (0.69,1.58) 0.83|
| Age ≥ 57                   | 1.24 (0.67,2.32) 0.49  | 0.67 (0.31,1.39) 0.27  | 0.97 (0.64,1.45) 0.87|
| Female                     | 1.08 (0.38,3.04) 0.89  | 0.55 (0.16,1.89) 0.34  | 0.85 (0.42,1.70) 0.64|
| Male                       | 1.26 (0.79,2.02) 0.34  | 0.80 (0.44,1.43) 0.45  | 1.04 (0.76,1.42) 0.82|
| Non-smoke                  | 1.18 (0.57,2.45) 0.65  | 0.64 (0.25,1.67) 0.37  | 0.95 (0.58,1.58) 0.86|
| Smoke                      | 1.19 (0.70,2.03) 0.53  | 0.78 (0.41,1.48) 0.45  | 1.00 (0.70,1.42) 1.00|
| Non-small-cell lung cancer | 1.09 (0.67,1.76) 0.73  | 0.82 (0.44,1.51) 0.52  | 0.98 (0.71,1.36) 0.91|
| Squamous-cell carcinoma    | 1.06 (0.53,2.11) 0.87  | 1.02 (0.46,2.26) 0.97  | 1.03 (0.66,1.61) 0.9|
| Adenocarcinoma             | 1.17 (0.58,2.35) 0.66  | 0.47 (0.19,1.39) 0.17  | 0.90 (0.54,1.49) 0.67|
| Small-cell lung cancer     | 0.74 (0.20,2.73) 0.65  | 0.87 (0.11,6.74) 0.89  | 0.81 (0.30,2.21) 0.68|
| Stage (III, IV)            | 1.01 (0.64,1.59) 0.98  | 0.72 (0.40,1.29) 0.27  | 0.91 (0.66,1.25) 0.55|
| Cisplatin                  | 1.19 (0.74,1.92) 0.46  | 0.81 (0.46,1.64) 0.47  | 1.01 (0.74,1.39) 0.93|
| Carboplatin                | 1.46 (0.53,4.02) 0.46  | 0.61 (0.16,3.27) 0.48  | 1.05 (0.52,2.10) 0.89|
| Platinum/gemcitabine       | 0.80 (0.43,1.50) 0.49  | 0.90 (0.42,1.90) 0.77  | 0.88 (0.58,1.33) 0.54|
| Platinum/etoposide         | 0.65 (0.19,2.17) 0.48  | 0.84 (0.13,3.57) 0.86  | 0.75 (0.30,1.88) 0.54|
| Platinum/pemetrexed        | 1.25 (0.50,3.12) 0.64  | 0.75 (0.39,1.37) 0.41  | 0.72 (0.37,1.40) 0.33|

OR: Odd ratio; CI: Confidence interval.

4. Discussion

It was reported that the SNP rs10505477 in CASC8 gene is related to risk of several solid tumor malignancies, such as CRC [29,30], gastric cancer [22,31] and invasive ovarian cancer [32]. Study by Sen et al., demonstrated that rs10505477 might be involved in the prognosis of gastric cancer patients receiving cisplatin-based chemotherapy after surgical treatment [20]. However, there is no study investigating the relationship between the SNP rs10505477 polymorphism and platinum-based chemotherapy toxicity in any cancer. For the first time, our study showed that lncRNA CASC8 rs10505477 polymorphism was significantly related to lung cancer susceptibility, platinum-based chemotherapy response and toxicity.
The mechanism by which the SNP rs10505477 modify cancer risk is still unclear. Several hypotheses have been put forward. First, rs10505477 is located in the intronic region of IncRNA CASC8, Ma et al. [22] hypothesized that it may affect the function of CASC8 through changing its folding structures, disrupting the critical regulatory region of CASC8 and leading to its dysregulated expression. Second, probably, rs10505477 allele could alter the interactions between the CASC8 and its cognate gene POU5F1B (POU class 5 homeobox 1 pseudogene 1), an acknowledged tumor susceptibility gene [33], by regulating the binding of some transcription factors to promoter of POU5F1B gene. Third, it was reported that there existed a strong linkage disequilibrium (LD) between the SNP rs10505477 and the SNP rs6983267, which is also located at 8q24 and has been reported to be related to tumorigenesis [2,22,34,35]. Evidence suggests that the GG genotype of rs6983267 was greatly related to increased lung cancer risk in Han Chinese [35]. Many other studies have also demonstrated the significant association between rs6983267 GG genotype and high risk of several other cancers, such as CRC, prostate cancer, and kidney cancer [26,36,37]. Furthermore, it was reported that the SNP rs6983267 was correlated with the increased CRC risk by enhancing the response to Wnt signaling pathway and combination with promoter of MYC [38–40], which was aberrantly expressed in many kinds of cancers, including lung cancer [41]. The SNP rs6983267 also could interact with β-catenin-TCF4 complex and promotes the tumorigenesis of CRC. Therefore, probably, the rs10505477 locus could indirectly affect the susceptibility of cancer through its connection with the cancer risk-related rs6983267 mutant. However, the possible role of these two variant and their LD on the function of contiguous gene in risk of cancers including lung cancer warrants further investigation.

It has been reported that CASC8 gene is located at 8q24, a “gene-desert” region, and overlaps POU5F1B gene [20,22], which is identified to be highly homologous to POU5F1 (POU class 5 homeobox 1) gene, also called OCT3 or OCT4 [42]. Additionally, Panagopoulos et al., have reported that POU5F1B could produce a protein with similar function to POU5F1 [43]. Study by Hosokawa et al., demonstrated that OCT-3/4 expression was well related to ATP binding cassette transporter G2 (ABCG2), a drug efflux pump gene, in glioblastoma samples, and OCT-3/4 could strengthen the resistance of chemotherapeutic drugs, such as doxorubicin, carboplatin, and etoposide phosphate, in glioblastoma cell lines by elevating the expression of ABCG2 [44]. Ota et al. [45] found that NSCLC patients that over expressed ABCG2 showed resistance to platinum-based treatment, they claimed that ABCG2 might serve as a molecular target for decreasing platinum-based chemotherapeutic resistance. Taken together, we speculate that, probably, IncRNA CASC8 rs10505477 polymorphism could affect the efficacy and toxicity of platinum-based chemotherapeutic drugs through POU5F1B-OCT-3/4-ABCG2 axis in lung cancer patients.

Finally, some deficiencies in the present study must be taken into account. First, despite that strong correlations between rs10505477 and lung cancer risk, platinum-based chemotherapy response and toxicity were observed, how this genetic variant influence CASC8 still need further investigation. Second, only one SNP, rs10505477, was chosen in the present study, other SNPs such as rs6983267 which was linked with the SNP rs10505477 in the 8q24 region were not included. Third, all patients recruited in this study were from only two hospitals in the same city, and the number of samples was not sufficient enough.

5. Conclusions

In summary, for the first time, we explored the effect of CASC8 rs10505477 polymorphism on lung cancer susceptibility, platinum-based chemotherapy response, and toxicity. Thus, the SNP rs10505477 in CASC8 may serve as an underlying risk marker for detecting and diagnosing lung cancer, and could be used to determine the response and toxicity of platinum-based chemotherapy in lung cancer patients. However, further larger well-designed studies will be needed to clarify the biological and clinical significance of the rs10505477 polymorphism and its LD with rs6983267 in lung cancer risk, platinum-based chemotherapy response, and toxicity.
Acknowledgments: This study was supported by the National Natural Science Foundation of China (No. 81503563).

Author Contributions: Lei Hu analyzed the data and wrote the paper. Hong-Hao Zhou designed the study and revised the whole paper. Shu-Hui Chen, Qiao-Li Lv, Bao Sun, Qiang Qu, Chong-Zhen Qin, Lan Fan, Ying Guo and Lin Cheng revised the whole paper. All authors approved the final version of this paper.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
2. Gong, W.J.; Yin, J.Y.; Li, X.P.; Fang, C.; Xiao, D.; Zhang, W.; Zhou, H.H.; Li, X.; Liu, Z.Q. Association of well-characterized lung cancer IncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumour Biol. 2016, 37, 8349–8358. [CrossRef] [PubMed]
3. Albright, F.; Teerlink, C.; Werner, T.L.; Cannon-Albright, L.A. Significant evidence for a heritable contribution to cancer predisposition: A review of cancer familiality by site. BMC Cancer 2012, 12, 138. [CrossRef] [PubMed]
4. Brennan, P.; Hainaut, P.; Boffetta, P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011, 12, 399–408. [CrossRef] [PubMed]
5. Cole, M.L.; Liu, M.; Bonassi, S.; Neri, M.; Schwartz, A.G.; Christiani, D.C.; Spitz, M.R.; Muscat, J.E.; Rennert, G.; Aben, K.K.; et al. Increased risk of lung cancer in individuals with a family history of the disease: A pooled analysis from the international lung cancer consortium. Eur. J. Cancer 2012, 48, 1957–1968. [CrossRef] [PubMed]
6. Meyerson, M.; Carbone, D. Genomic and proteomic profiling of lung cancers: Lung cancer classification in the age of targeted therapy. J. Clin. Oncol. 2005, 23, 3219–3226. [CrossRef] [PubMed]
7. Granville, C.A.; Dennis, P.A. An overview of lung cancer genomics and proteomics. Am. J. Respir. Cell Mol. Biol. 2005, 32, 169–176. [CrossRef] [PubMed]
8. Liu, K.; Lin, Q.; Ding, H.; Jin, Y.; Chen, G. Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients. Int. J. Clin. Exp. Med. 2015, 8, 20918–20924. [PubMed]
9. Hong, M.J.; Lee, S.Y.; Choi, J.E.; Jin, C.C.; Kang, H.J.; Back, S.A.; Lee, S.Y.; Shin, K.M.; Jeong, J.Y.; Lee, W.K.; et al. A genetic variation in mircoRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer. Oncotarget 2016. [CrossRef] [PubMed]
10. Chen, J.; Wu, L.; Wang, Y.; Yin, J.; Li, X.; Wang, Z.; Li, H.; Zou, T.; Qian, C.; Li, C.; et al. Effect of transporter and DNA repair gene polymorphisms to lung cancer chemotherapy toxicity. Tumour Biol. 2016, 37, 2275–2284. [CrossRef] [PubMed]
11. Johnson, C.; Pankratz, V.S.; Velazquez, A.I.; Aakre, J.A.; Loprinzi, C.L.; Staff, N.P.; Windebank, A.J.; Yang, P. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J. Neurol. Sci. 2015, 349, 124–128. [CrossRef] [PubMed]
12. Okazaki, Y.; Furuno, M.; Kasukawa, T.; Adachi, J.; Bono, H.; Kondo, S.; Nakaide, I.; Osato, N.; Saito, R.; Suzuki, H.; et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cdnas. Nature 2002, 420, 563–573. [CrossRef] [PubMed]
13. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464, 1071–1076. [CrossRef] [PubMed]
14. Tripathi, V.; Ellis, J.D.; Shen, Z.; Song, D.Y.; Pan, Q.; Watt, A.T.; Freier, S.M.; Bennett, C.F.; Sharma, A.; Bubulya, P.A.; et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 2010, 39, 925–938. [CrossRef] [PubMed]
15. Shang, C.; Guo, Y.; Zhang, H.; Xue, Y.X. Long noncoding rna hotair is a prognostic biomarker and inhibits chemo sensitivity to doxorubicin in bladder transitional cell carcinoma. Cancer Chemother. Pharmacol. 2016, 77, 507–513. [CrossRef] [PubMed]
16. Morris, K.V. Long antisense non-coding rnas function to direct epigenetic complexes that regulate transcription in human cells. Epigenetics 2009, 4, 296–301. [CrossRef] [PubMed]
17. Han, L.; Zhang, K.; Shi, Z.; Zhang, J.; Zhu, J.; Zhu, S.; Zhang, A.; Jia, Z.; Wang, G.; Yu, S.; et al. LncRNA profile of glioblastoma reveals the potential role of lncRNAs in contributing to glioblastoma pathogenesis. *Int. J. Oncol.* **2012**, *40*, 2004–2012. [PubMed]

18. Hauptman, N.; Glavac, D. Long non-coding RNA in cancer. *Int. J. Mol. Sci.* **2013**, *14*, 4655–4669. [CrossRef] [PubMed]

19. Ricciuti, B.; Mencaroni, C.; Pagliaungla, L.; Paciullo, F.; Crino, L.; Chiari, R.; Metro, G. Long noncoding RNAs: New insights into non-small cell lung cancer biology, diagnosis and therapy. *Med. Oncol.* **2016**, *33*, 18. [CrossRef] [PubMed]

20. Shen, L.; Du, M.; Wang, C.; Gu, D.; Wang, M.; Zhang, Q.; Zhao, T.; Zhang, X.; Tan, Y.; Huo, X.; et al. Clinical significance of pou5f1p1 rs10505477 polymorphism in Chinese gastric cancer patients receiving cisplatin-based chemotherapy after surgical resection. *Int. J. Mol. Sci.* **2014**, *15*, 12764–12777. [CrossRef] [PubMed]

21. Dai, J.; Gu, J.; Huang, M.; Eng, C.; Kopetz, E.S.; Ellis, L.M.; Hawk, E.; Wu, X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. *Carcinogenesis* **2012**, *33*, 1327–1331. [CrossRef] [PubMed]

22. Ma, G.; Gu, D.; Lv, C.; Chu, H.; Xu, Z.; Tong, N.; Wang, M.; Tang, C.; Xu, Y.; Zhang, Z.; et al. Genetic variant in 8q24 is associated with prognosis for gastric cancer in a Chinese population. *J. Gastroenterol. Hepatol.* **2015**, *30*, 689–695. [CrossRef] [PubMed]

23. Yeager, M.; Orr, N.; Hayes, R.B.; Jacobs, K.B.; Kraft, P.; Wacholder, S.; Minichiello, M.J.; Fearnhead, P.; Yu, K.; Chatterjee, N.; et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. *Nat. Genet.* **2007**, *39*, 645–649. [CrossRef] [PubMed]

24. Zanke, B.W.; Greenwood, C.M.; Rangej, J.; Kustra, R.; Tenesa, A.; Farrington, S.M.; Prendergast, J.; Olschwang, S.; Chiang, T.; Crowdy, E.; et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. *Nat. Genet.* **2007**, *39*, 989–994. [CrossRef] [PubMed]

25. He, J.; Wilkens, L.R.; Stram, D.O.; Kolonel, L.N.; Henderson, B.E.; Wu, A.H.; Le Marchand, L.; Haiman, C.A. Generalizability and epidemiologic characterization of eleven colorectal cancer GWAS hits in multiple populations. *Cancer Epidemiol. Biomark. Prev.* **2011**, *20*, 70–81. [CrossRef] [PubMed]

26. Tomlinson, I.; Webb, E.; Carvajal-Carmona, L.; Broderick, P.; Kemp, Z.; Spain, S.; Penegar, S.; Chandler, L.; Gorman, M.; Wood, W.; et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. *Nat. Genet.* **2007**, *39*, 984–988. [CrossRef] [PubMed]

27. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; van Glabbeke, M.; van Oosterom, A.T.; Christian, M.C.; et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. *J. Natl. Cancer Inst.* **2000**, *92*, 205–216. [CrossRef]

28. PLINK. Available online: http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml (accessed on 15 May 2014).

29. Yao, K.; Hua, L.; Wei, L.; Meng, J.; Hu, J. Correlation between CASC8, SMAD7 polymorphisms and the susceptibility to colorectal cancer: A systematic and updated meta-analysis. *Medicine* **2015**, *94*, e1884. [CrossRef] [PubMed]

30. Li, L.; Lv, L.; Liang, Y.; Shen, X.; Zhou, S.; Zhui, J.; Ma, R. Association of 8q23–24 region (8q23.3 loci and 8q24.21 loci) with susceptibility to colorectal cancer: A systematic and updated meta-analysis. *Int. J. Clin. Exp. Med.* **2015**, *8*, 21001–21013. [PubMed]

31. Zhou, C.P.; Pan, H.Z.; Li, F.X.; Hu, N.Y.; Li, M.; Yang, X.X. Association analysis of colorectal cancer susceptibility variants with gastric cancer in a Chinese Han population. *Genet. Mol. Res.* **2014**, *13*, 3673–3680. [CrossRef] [PubMed]

32. Ghoussaini, M.; Song, H.; Koesслer, T.; Al Olama, A.A.; Kote-Jarai, Z.; Driver, K.E.; Pooley, K.A.; Ramus, S.J.; Kjaer, S.K.; Hogdall, E.; et al. Multiple loci with different cancer specificities within the 8q24 gene desert. *J. Natl. Cancer Inst.* **2008**, *100*, 962–966. [CrossRef] [PubMed]

33. Kastler, S.; Honold, L.; Luedeke, M.; Kuefer, R.; Moller, P.; Hoegel, J.; Vogel, W.; Maier, C.; Assum, G. Pou5f1p1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. *Prostate* **2010**, *70*, 666–674. [CrossRef] [PubMed]

34. Haerian, M.S.; Baum, L.; Haerian, B.S. Association of 8q24.21 loci with the risk of colorectal cancer: A systematic review and meta-analysis. *J. Gastroenterol. Hepatol.* **2011**, *26*, 1475–1484. [CrossRef] [PubMed]
35. Zhang, X.; Chen, Q.; He, C.; Mao, W.; Zhang, L.; Xu, X.; Zhu, J.; Chen, B. Polymorphisms on 8q24 are associated with lung cancer risk and survival in Han Chinese. *PLoS ONE* **2012**, *7*, e41930. [CrossRef] [PubMed]

36. Daraei, A.; Salehi, R.; Salehi, M.; Emami, M.H.; Janghorbani, M.; Mohamadhashem, F.; Tavakoli, H. Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in *EGF* gene on the risk of sporadic colorectal cancer in Iranian population. *Med. Oncol.* **2012**, *29*, 1044–1049. [CrossRef] [PubMed]

37. Wokolorczyk, D.; Gliniewicz, B.; Sikorski, A.; Złowocka, E.; Masoje, B.; Debniak, T.; Matyjasik, J.; Mierzewski, M.; Medrek, K.; Osztowska, D.; et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. *Cancer Res.* **2008**, *68*, 9982–9986. [CrossRef] [PubMed]

38. Pomerantz, M.M.; Ahmadiyeh, N.; Jia, L.; Herman, P.; Verzi, M.P.; Doddapaneni, H.; Beckwith, C.A.; Chan, J.A.; Hills, A.; Davis, M.; et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with myc in colorectal cancer. *Nat. Genet.* **2009**, *41*, 882–884. [CrossRef] [PubMed]

39. Tuupanen, S.; Turunen, M.; Lehtonen, R.; Hallikas, O.; Vanharanta, S.; Kivioja, T.; Bjorklund, M.; Wei, G.; Yan, J.; Niittymaki, I.; et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. *Nat. Genet.* **2009**, *41*, 885–890. [CrossRef] [PubMed]

40. Harismendy, O.; Frazer, K.A. Elucidating the role of 8q24 in colorectal cancer. *Nat. Genet.* **2009**, *41*, 868–869. [CrossRef] [PubMed]

41. Ye, L.; Wang, W.; Chen, C.; Meng, Q.; Yu, Y. Study of circulating IgG antibodies to BIRC5 and MYC in non-small cell lung cancer. *FEBS Open Biol.* **2015**, *5*, 809–812. [CrossRef] [PubMed]

42. Suo, G.; Han, J.; Wang, X.; Zhang, J.; Zhao, Y.; Zhao, Y.; Dai, J. Oct4 pseudogenes are transcribed in cancers. *Biochem. Biophys. Res. Commun.* **2005**, *337*, 1047–1051. [CrossRef] [PubMed]

43. Panagopoulos, I.; Moller, E.; Collin, A.; Mertens, F. The POUSF1P1 pseudogene encodes a putative protein similar to POUSF1 isoform 1. *Oncol. Rep.* **2008**, *20*, 1029–1033. [CrossRef] [PubMed]

44. Hosokawa, Y.; Takahashi, H.; Inoue, A.; Kawabe, Y.; Funahashi, Y.; Kameda, K.; Sugimoto, K.; Yano, H.; Harada, H.; Kohno, S.; et al. Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2. *Biochim. Biophys. Acta* **2015**, *1850*, 1197–1205. [CrossRef] [PubMed]

45. Ota, S.; Ishii, G.; Goto, K.; Kubota, K.; Kim, Y.H.; Kojika, M.; Murata, Y.; Yamazaki, M.; Nishiwaki, Y.; Eguchi, K.; et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. *Lung Cancer* **2009**, *64*, 98–104. [CrossRef] [PubMed]